<p>近年来，我们看到几种投资趋势席卷华尔街，从对大麻市场的兴奋到现在主导头条的人工智能（AI）行业。这些机会中的一些最终成为了重大失望，而另一些则是巨大的赚钱机会。</p>
<p>虽然寻求在新兴高增长行业中获利没有错，但实施一些经过时间考验的策略，例如投资于分红股票，也是值得的——这是一种永不过时的投资风格。</p>
<p>如果你现在正在寻找顶级的分红支付公司来投资，让我们考虑两个优秀的候选者：<strong>苹果</strong>(AAPL -0.17%) 和 <strong>诺华</strong>(NVS 0.85%)。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg5ODQvcGVyc29uLXNpdHRpbmctYW5kLXdvcmtpbmctYXQtYS1kZXNrLmpwZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="700" height="466" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg5ODQvcGVyc29uLXNpdHRpbmctYW5kLXdvcmtpbmctYXQtYS1kZXNrLmpwZyZ3PTcwMA"/></p>
<p>图片来源：Getty Images。</p>
<h2>1. 苹果</h2>
<p>由于特朗普总统的激进贸易政策，苹果今年一直面临压力。这家科技巨头大部分 iPhone 在国外生产，尤其是在中国。政府对进口商品征收了高额关税，这可能会侵蚀苹果的利润。然而，该公司的首席执行官蒂姆·库克最近与特朗普达成了一项协议，允许苹果在增加对美国制造业投资至 6000 亿美元的条件下，免除一些潜在的有害关税。</p>
<p>这些发展减轻了苹果面临的关税威胁，使得该股票更加吸引人。尽管公司的收入增长速度不再像以前那样快，但它仍然拥有强大的业务和良好的长期前景。在其最新的财报期（2025 财年的第三季度，截止至 6 月 28 日），销售额同比增长 10%，达到 940 亿美元，而每股收益同比跃升 12%，达到 1.57 美元。</p>
<p>在过去 12 个月中，苹果产生了 962 亿美元的自由现金流（FCF）。尽管与去年同期相比，FCF 下降了 11.6%，但这仍然是可支配的巨额现金，可以再投资于业务以改善财务业绩。</p>
<p>它可以通过寻找更多方式来实现其庞大生态系统的货币化。该公司在其服务部门拥有超过 20 亿活跃设备和超过 10 亿个付费订阅，这些服务的利润率远高于其他业务。</p>
<p>此外，苹果仍在寻求在 AI 市场上发力。尽管它落后于一些科技同行，但该公司常常在市场上迟到，随后推出一款其忠实客户群体喜爱的设备，最终取得巨大的成功。</p>
<p>最后，苹果是一只稳健的分红股票。该公司在过去十年中将分红翻了一番，现金分红比率仍然保持在 14% 的适度水平。尽管苹果最近面临一些逆风，但它正在证明自己应对这些挑战的能力。对于长期投资者来说，这只股票看起来非常有吸引力。</p>
<h2>2. 诺华</h2>
<p>诺华是一家领先的制药公司，今年的表现优于大盘股票。尽管公司面临一些逆风——例如关税威胁，以及即将到来的 Entresto（心力衰竭药物及其畅销药物）的仿制药竞争——但其财务业绩依然强劲。在第二季度，净销售额同比增长 12%，达到 141 亿美元，而净收入增长 24%，达到 40 亿美元。</p>
<p>确实，在第二季度，Entresto 的仿制药竞争者尚未进入市场，但诺华仍然预计今年的收入增长将达到高个位数，并且最近提高了其营业收入指引。对于一家即将失去其畅销药物的公司来说，这一点令人印象深刻。这表明诺华的几个关键方面，包括其多样化的产品线，拥有多个重磅药物。</p>
<p>在 2025 年的前六个月，该公司的七种产品的年销售额均已超过 10 亿美元。</p>
<p>诺华在开发新药方面也表现出色。它将能够通过一些相对较新的产品来抵消与 Entresto 相关的损失，包括 2020 年在美国首次获批的多发性硬化症药物 Kesimpta，以及 2022 年首次获得批准的癌症药物 Pluvicto。</p>
<p>即使是更新的药物，也将帮助推动收入增长，直到下个十年，包括今年刚获批的 Vanrafia，用于降低某些患者尿液中的高蛋白水平，以及 2023 年推出的 Fabhalta，一种用于某些罕见血液和肾脏疾病的药物。</p>
<p>这些特质正是制药公司在长期内表现良好的必要条件。作为其长期性的进一步证据，诺华已经连续 28 年提高分红。这家制药巨头看起来是一只出色的股票，适合在市场下跌和波动时买入并持有。那些寻找永恒分红股票的人应该强烈考虑诺华。</p>

苹果

2 倍做多 AAPL ETF - GraniteShares

苹果每日 1 倍做空 ETF - Direxion

苹果每日 2 倍做多 ETF - Direxion

AAPX

AAPY

APLY

<p>本文讨论了两个值得考虑的分红股票：苹果和诺华。苹果由于关税面临挑战，但已达成协议以增加美国制造投资，财务状况保持强劲，销售额增长 10%，并且拥有稳健的分红历史。尽管诺华面临仿制药竞争，但其销售额增长了 12%，并且产品线多样化，确保了持续增长。由于这两家公司强大的商业模式和稳定的分红支付，建议进行长期投资</p>

<p>We've seen several investing trends sweep through Wall Street in recent years, from excitement about the cannabis market to the artificial intelligence (AI) industry that's now dominating headlines. Some of these opportunities turned out to be major disappointments, while others were major moneymakers.</p>
<div class="lb-trans"><p>近年来，我们看到几种投资趋势席卷华尔街，从对大麻市场的兴奋到现在主导头条的人工智能（AI）行业。这些机会中的一些最终成为了重大失望，而另一些则是巨大的赚钱机会。</p>
</div><p>Although there's nothing wrong with looking to capitalize on new high-growth industries, it's also worth implementing time-tested strategies such as investing in dividend stocks -- that's one investment style that will never die.</p>
<div class="lb-trans"><p>虽然寻求在新兴高增长行业中获利没有错，但实施一些经过时间考验的策略，例如投资于分红股票，也是值得的——这是一种永不过时的投资风格。</p>
</div><p>And if you're looking for top dividend-paying companies to put your money in right now, let's consider two excellent candidates: <strong>Apple</strong>(AAPL -0.17%) and <strong>Novartis</strong>(NVS 0.85%).</p>
<div class="lb-trans"><p>如果你现在正在寻找顶级的分红支付公司来投资，让我们考虑两个优秀的候选者：<strong>苹果</strong>(AAPL -0.17%) 和 <strong>诺华</strong>(NVS 0.85%)。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg5ODQvcGVyc29uLXNpdHRpbmctYW5kLXdvcmtpbmctYXQtYS1kZXNrLmpwZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F828984%2Fperson-sitting-and-working-at-a-desk.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><h2>1. Apple</h2>
<div class="lb-trans"><h2>1. 苹果</h2>
</div><p>Apple has been under pressure all year due to President Donald Trump's aggressive trade policies. The tech leader manufactures most of its iPhones abroad, especially in China. The administration has been imposing stiff tariffs on imports, which could erode Apple's profits. However, the company's CEO, Tim Cook, recently reached a deal with Trump that will exempt Apple from some potentially damaging tariffs in exchange for increasing its investment in U.S. manufacturing to $600 billion.</p>
<div class="lb-trans"><p>由于特朗普总统的激进贸易政策，苹果今年一直面临压力。这家科技巨头大部分 iPhone 在国外生产，尤其是在中国。政府对进口商品征收了高额关税，这可能会侵蚀苹果的利润。然而，该公司的首席执行官蒂姆·库克最近与特朗普达成了一项协议，允许苹果在增加对美国制造业投资至 6000 亿美元的条件下，免除一些潜在的有害关税。</p>
</div><p>These developments mitigate the threat from tariffs for Apple, making the stock even more attractive. Though the company no longer grows its revenue as fast as it once did, it still has a robust business and good long-term prospects. In its latest period (the third quarter of its fiscal year 2025, which ended June 28), sales increased by 10% year over year to $94 billion, while earnings per share jumped 12% year over year to $1.57.</p>
<div class="lb-trans"><p>这些发展减轻了苹果面临的关税威胁，使得该股票更加吸引人。尽管公司的收入增长速度不再像以前那样快，但它仍然拥有强大的业务和良好的长期前景。在其最新的财报期（2025 财年的第三季度，截止至 6 月 28 日），销售额同比增长 10%，达到 940 亿美元，而每股收益同比跃升 12%，达到 1.57 美元。</p>
</div><p>Apple has generated $96.2 billion in free cash flow (FCF) over the trailing-12-month period. Although FCF has declined by 11.6% compared to the same time last year, that's still a substantial amount of cash at its disposal, which it can reinvest in the business to improve its financial results.</p>
<div class="lb-trans"><p>在过去 12 个月中，苹果产生了 962 亿美元的自由现金流（FCF）。尽管与去年同期相比，FCF 下降了 11.6%，但这仍然是可支配的巨额现金，可以再投资于业务以改善财务业绩。</p>
</div><p>It could achieve this by finding more ways to monetize its vast ecosystem. The company has more than 2 billion active devices and over 1 billion paid subscriptions within its services segment, which boasts much juicier margins than the rest of the business.</p>
<div class="lb-trans"><p>它可以通过寻找更多方式来实现其庞大生态系统的货币化。该公司在其服务部门拥有超过 20 亿活跃设备和超过 10 亿个付费订阅，这些服务的利润率远高于其他业务。</p>
</div><p>Moreover, Apple is still looking to make waves in the AI market. Although it trails some of its tech peers, the company has often been late to the party, only to launch a device that its loyal base of customers loves and that ends up becoming massively successful.</p>
<div class="lb-trans"><p>此外，苹果仍在寻求在 AI 市场上发力。尽管它落后于一些科技同行，但该公司常常在市场上迟到，随后推出一款其忠实客户群体喜爱的设备，最终取得巨大的成功。</p>
</div><p>Finally, Apple is a solid dividend stock. The company has doubled its payouts over the past decade and still has a modest cash payout ratio of 14%. Apple may have faced some headwinds recently, but it's proving its ability to navigate them. The stock looks highly attractive for long-term investors.</p>
<div class="lb-trans"><p>最后，苹果是一只稳健的分红股票。该公司在过去十年中将分红翻了一番，现金分红比率仍然保持在 14% 的适度水平。尽管苹果最近面临一些逆风，但它正在证明自己应对这些挑战的能力。对于长期投资者来说，这只股票看起来非常有吸引力。</p>
</div><h2>2. Novartis</h2>
<div class="lb-trans"><h2>2. 诺华</h2>
</div><p>Novartis, a leading pharmaceutical company, has outperformed broader equities this year. Although the company faces some headwinds -- such as the threat of tariffs, and upcoming generic competition for Entresto, a medicine for heart failure and its top-selling drug -- its financial results remain strong. In the second quarter, net sales increased by 12% year over year to $14.1 billion, while net income rose 24% to $4 billion.</p>
<div class="lb-trans"><p>诺华是一家领先的制药公司，今年的表现优于大盘股票。尽管公司面临一些逆风——例如关税威胁，以及即将到来的 Entresto（心力衰竭药物及其畅销药物）的仿制药竞争——但其财务业绩依然强劲。在第二季度，净销售额同比增长 12%，达到 141 亿美元，而净收入增长 24%，达到 40 亿美元。</p>
</div><p>True, Entresto's generic competitors hadn't entered the market yet in the second quarter, but Novartis continues to expect top-line growth in the high single digits for the year, and it recently increased its operating income guidance. For a company about to lose its best-selling medicine, that's impressive. It points to several key aspects of Novartis, including its diversified lineup featuring multiple blockbusters.</p>
<div class="lb-trans"><p>确实，在第二季度，Entresto 的仿制药竞争者尚未进入市场，但诺华仍然预计今年的收入增长将达到高个位数，并且最近提高了其营业收入指引。对于一家即将失去其畅销药物的公司来说，这一点令人印象深刻。这表明诺华的几个关键方面，包括其多样化的产品线，拥有多个重磅药物。</p>
</div><p>Through the first six months of 2025, seven of the company's products had already exceeded $1 billion each in annual sales.</p>
<div class="lb-trans"><p>在 2025 年的前六个月，该公司的七种产品的年销售额均已超过 10 亿美元。</p>
</div><p>Novartis is also excellent at developing new medicines. It will be able to offset Entresto-related losses thanks to some relatively newer products, including Kesimpta for multiple sclerosis, first approved in the U.S. in 2020, and Pluvicto, a cancer medicine that first earned the green light in 2022.</p>
<div class="lb-trans"><p>诺华在开发新药方面也表现出色。它将能够通过一些相对较新的产品来抵消与 Entresto 相关的损失，包括 2020 年在美国首次获批的多发性硬化症药物 Kesimpta，以及 2022 年首次获得批准的癌症药物 Pluvicto。</p>
</div><p>Even newer medicines that will help drive top-line growth well into the next decade include Vanrafia, approved just this year to reduce high levels of protein in urine for certain patients, and Fabhalta, a medicine for some rare blood and kidney disorders, launched in 2023.</p>
<div class="lb-trans"><p>即使是更新的药物，也将帮助推动收入增长，直到下个十年，包括今年刚获批的 Vanrafia，用于降低某些患者尿液中的高蛋白水平，以及 2023 年推出的 Fabhalta，一种用于某些罕见血液和肾脏疾病的药物。</p>
</div><p>These qualities are precisely what a drugmaker needs to perform well over the long run. As further evidence of its longevity, note that Novartis has increased its dividends for 28 consecutive years. The pharmaceutical giant looks like an outstanding stock to buy and hold through market downturns and volatility. Those looking for forever dividend stocks should strongly consider Novartis.</p>
<div class="lb-trans"><p>这些特质正是制药公司在长期内表现良好的必要条件。作为其长期性的进一步证据，诺华已经连续 28 年提高分红。这家制药巨头看起来是一只出色的股票，适合在市场下跌和波动时买入并持有。那些寻找永恒分红股票的人应该强烈考虑诺华。</p>
</div>

2 Dividend Stocks to Buy and Hold

- 文章讨论了苹果和诺华作为优质股息股票的投资潜力。  
- 苹果在贸易政策压力下仍实现销售增长，股息持续增加。  
- 诺华在面临竞争的情况下，销售和净收入均显著增长，股息连续 28 年上调。

两只值得买入并长期持有的股息股票